Уноси

• The Implementation of Managed Entry Agreements in Central and Eastern Europe: Findings and Implications (2017-08)

  A. Ferrario, D. Araja, T. Bochenek, T. Ćatić, D. Danko, M. Dimitrova, J. Furst, I. Greičiute-Kuprijanov, I. Hoxha, A. Jakupi, E. Laidmae, O. Loblova, I. Mardare, V. Marković Peković, D. Meshkov, T. Novakovic, G. Petrova, M. Pomorski, D. Tomek, L. Vončina, A. Haycox, P. Kanavos, P. Vella Bonanno, B. Godman, The Implementation of Managed Entry Agreements in Central and Eastern Europe: Findings and Implications, PHARMACOECONOMICS, pp. 1 - 15, Aug, 2017

• Systematic Measures and Legislative and Organizational Frameworks Aimed at Preventing or Mitigating Drug Shortages in 28 European and Western Asian Countries (2018-01)

  T. Bochenek, V. Abilova, A. Alkan, B. Asanin, I. Beriain, Z. Besovic, P. Vella Bonanno, A. Bucsics, M. Davidescu, E. de Weerdt, N. Duborija-Kovacevic, J. Furst, M. Gaga, E. Gailite, J. Gulbinovic, E. Gurpinar, B. Hanko, V. Hargaden, T. Hotvedt, I. Hoxha, I. Huys, A. Inotai, A. Jakupi, H. Jenzer, R. Joppi, O. Laius, M. Lenormand, D. Makridaki, A. Malaj, K. Margus, V. Marković Peković, N. Miljkovic, J. de Miranda, S. Primozic, D. Rajinac, D. schwartz, R. Sebesta, S. Simoens, J. Slaby, L. Sović-Brkičić, T. Tesar, L. Tzirnis, E. Warminska, B. Godman, Systematic Measures and Legislative and Organizational Frameworks Aimed at Preventing or Mitigating Drug Shortages in 28 European and Western Asian Countries, Frontiers in Pharmacology, Vol. 8, No. article 942, pp. 1 - 23, Jan, 2018

• Barriers for Access to New Medicines: Searching for the Balance Between Rising Costs and Limited Budgets (2018-12)

  B. Godman, A. Bucsics, P. Vella Bonanno, W. Oortwijn, C. Rothe, A. Ferrario, S. Bosselli, A. Hill, A. Martin, S. Simoens, A. Kurdi, M. Gad, J. Gulbinovic, A. Timoney, T. Bochenek, A. Salem, I. Hoxha, R. Sauermann, A. Massele, A. Guerra Junior, G. Petrova, Z. Mitkova, G. Achniotou, O. Laius, C. Sermet, G. Selke, V. Kourafalos, J. Yfantopoulos, E. Magnusson, R. Joppi, M. Oluka, H. Kwon, A. Jakupi, F. Kalemeera, J. Fadare, O. Melien, M. Pomorski, M. Wladysiuk, V. Marković Peković, I. Mardare, D. Meshkov, T. Novakovic, J. Furst, D. Tomek, C. Zara, E. diogene, J. Meyer, R. Malmstrom, B. Wettermark, Z. Matsebula, S. Campbell, A. Haycox, Barriers for Access to New Medicines: Searching for the Balance Between Rising Costs and Limited Budgets, Frontiers in public health, Vol. 6, No. Article 328, pp. 1 - 21, Dec, 2018

• Proposal for a regulation on health technology assessment in Europe - opinions of policy makers, payers and academics from the field of HTA (2019-02)

  P. Vella Bonanno, A. Bucsics, S. Simoens, A. Martin, W. Oortwijn, J. Gulbinovic, C. Rothe, A. Timoney, A. Ferrario, M. Gad, A. Salem, I. Hoxha, R. Sauremann, M. Kamusheva, M. Dimitrova, G. Petrova, O. Laius, G. Selke, V. Kourafalos, J. Yfantopoulos, E. Magnusson, R. Joppi, A. Jakupi, T. Bochenek, M. Wladysiuk, C. Furtado, V. Marković Peković, I. Mardare, D. Meshkov, J. Furst, D. Tomek, M. Obach Cortadellas, C. Zara, A. Haycox, S. Campbell, B. Godman, Proposal for a regulation on health technology assessment in Europe - opinions of policy makers, payers and academics from the field of HTA, Expert Review of Pharmacoeconomics & Outcome Research, Vol. 19, No. 3, pp. 251 - 261, Feb, 2019

• Pricing of oral generic cancer medicines in 25 European countries; findings and implications (2019-02)

  B. Godman, A. Hill, S. Simoens, A. Kurdi, J. Gulbinovic, A. Margus, A. Timoney, D. Gotham, J. Wale, T. Bochenek, I. Hoxha, C. Rodrigues, C. Hierlander, A. Malaj, R. Sauremann, W. Hamelinck, Z. Mitkova, G. Petrova, O. Laius, C. Sermet, I. Langer, G. Selke, J. Yfantopoulos, R. Joppi, A. Jakupi, E. Poplavski, I. Greičiute-Kuprijanov, P. Vella Bonanno, H. Piepenbrink, V. Valk, C. Hagen, A. Ringerud, R. Plisko, M. Wladysiuk, V. Marković Peković, N. Grubiša, T. Ponorac, I. Mardare, T. Novakovic, M. Parker, J. Fraeyman, D. Tomek, M. Obach Cortadellas, C. Zara, M. Juhasz-Haverinen, P. Skiold, S. McTaggart, A. Heycox, Pricing of oral generic cancer medicines in 25 European countries; findings and implications, Generics and Biosimilars Initiative Journal, Vol. 8, No. 2, pp. 49 - 70, Feb, 2019

• Ongoing Strategies to Improve the Management of Upper Respiratory Tract Infections and Reduce Inappropriate Antibiotic Use Particularly Among Lower and Middle-Income Countries: Findings and Implications for the Future (2020-02)

  B. Godman, M. Haque, J. McKimm, M. Abu Bakar, J. Sneddoh, J. Wale, S. Campbell, A. Martin, I. Hoxha, V. Abilova, B. Paramadhas, P. Mpinda-Joseph, M. Matome, L. Lovato, I. Sefah, A. Kurdi, S. Opanga, A. Jakupi, Z. Saleem, M. Hassali, D. Kibule, J. Fadare, T. Bochenek, C. Rothe, J. Fraeyman, V. Marković Peković, Љ. Бојанић, N. Schellack, J. Meyer, Z. Matsebula, T. Phuong, B. Thanh, S. Jan, A. Kalungia, S. Matpuri-Ziyowera, M. Sartelli, R. Hill, Ongoing Strategies to Improve the Management of Upper Respiratory Tract Infections and Reduce Inappropriate Antibiotic Use Particularly Among Lower and Middle-Income Countries: Findings and Implications for the Future, CURRENT MEDICAL RESEARCH AND OPINION, Vol. 36, No. 2, pp. 301 - 327, Feb, 2020

• Fixed dose drug combinations - are they pharmacoeconomically sound? Findings and implications especially for lower- and middle-income countries (2020-02)

  B. Godman, H. McCabe, T. Leong, D. Mueller, A. Martin, I. Hoxha, J. Mwita, G. Rwegerera, A. Massele, J. Costa, R. Nascimento, L. Lovato, K. Tachkov, P. Milushewa, O. Patrick, L. Niba, O. Laius, I. Sefah, S. Abdulsalim, F. Soleymani, L. Achieng, A. Guantai, M. Oluka, A. Jakupi, K. Logviss, M. Hassali, D. Kibule, F. Kalemeera, M. Mubita, I. Mardare, A. Alrasheedy, J. Furst, D. Tomek, V. Marković Peković, T. Phuong, B. Thanh, A. Kalungia, T. Zaranyika, N. Masuka, I. Olaru, J. Wale, R. Hill, A. Kurdi, A. Timoney, S. Campbell, J. Meyer, Fixed dose drug combinations - are they pharmacoeconomically sound? Findings and implications especially for lower- and middle-income countries, Expert Review of Pharmacoeconomics & Outcome Research, Vol. 20, No. 1, pp. 1 - 26, Feb, 2020

• The Expiry of Humira® Market Exclusivity and the Entry of Adalimumab Biosimilars in Europe: An Overview of Pricing and National Policy Measures (2021-01)

  E. Moorkens, B. Godman, I. Huys, I. Hoxha, A. Malaj, S. Keuerleber, S. Stockinger, S. Mortenhuber, M. Dimitrova, K. Tachkov, L. Vlahović-Palčevski, V. Vlahović-Palčevski, G. Achniotou, J. Slaby, L. Popelkova, K. Kohoutova, D. Bartels, O. Laius, J. Martikainen, G. Selke, V. Kourafalos, E. Magnusson, R. Einarsdottir, R. Adams, R. Joppi, E. Allocati, A. Jakupi, A. Viksna, I. Greičiute-Kuprijanov, P. Vella Bonanno, V. Suttorp, O. Melien, R. Plisko, I. Mardare, D. Meshkov, T. Novakovic, J. Furst, C. Zara, V. Marković Peković, N. Grubiša, G. Befrits, R. Puckett, A. Vulto, The Expiry of Humira® Market Exclusivity and the Entry of Adalimumab Biosimilars in Europe: An Overview of Pricing and National Policy Measures, Frontiers in Pharmacology, pp. 1 - 17, Jan, 2021

• Variation in the prices of oncology medicines across Europe and the implications for the future (2021-02)

  B. Godman, S. Simoens, A. Kurdi, G. Selke, J. Yfantopoulos, A. hill, J. Gulbinovic, A. Martin, A. Timoney, D. Gotham, J. Wale, T. Bochenek, I. Selke Krulichova, E. Allocati, I. Hoxha, A. Malaj, C. Hierlander, A. Nachtnebel, W. Hamelinck, Z. Mitkova, G. Petrova, O. Laius, C. Sermet, I. Langer, R. Joppi, A. Jakupi, E. Poplavski, I. Greičiute-Kuprijanov, P. Vella Bonanno, H. Piepenbrink, V. de Valk, R. Plisko, M. Wladysiuk, V. Marković Peković, I. Mardare, T. Novakovic, M. Parker, J. Furst, D. Tomek, K. Banasova, M. Obach Cortadellas, C. Zara, C. Pontes, M. Juhasz-Haverinen, P. Skiold, S. McTaggart, D. Wong-Rieger, S. Campbell, R. Hill, Variation in the prices of oncology medicines across Europe and the implications for the future, Generics and Biosimilars Initiative Journal, Vol. 10, No. 2, pp. 72 - 82, Feb, 2021

• Potential approaches for the pricing of cancer medicines across Europe to enhance the sustainability of healthcare systems and the implications (2021-03)

  B. Godman, A. Hill, S. Simoens, G. Selke, I. Selke Krulichova, C. Zampirolli, A. Martin, W. Oortwijn, A. Timoney, L. Gustafsson, L. Vončina, H. Kwon, J. Gulbinovic, D. Gotham, J. Wale, W. da Silva, T. Bochenek, A. Kurdi, E. Allocati, O. Ogunleye, J. Meyer, I. Hoxha, A. Malaj, C. Hierlander, R. Sauremann, W. Hamelinck, G. Petrova, O. Laius, I. Langner, J. Yfantopoulos, R. Joppi, A. Jakupi, I. Greičiute-Kuprijanov, P. Vella Bonanno, H. Piepenbrink, V. de Valk, M. Wladysiuk, V. Marković Peković, I. Mardare, J. Furst, D. Tomek, M. Obach Cortadellas, C. Zara, C. Pontes, S. McTaggart, T. Laba, O. Melien, D. Wong-Rieger, S. Bae, R. Hill, Potential approaches for the pricing of cancer medicines across Europe to enhance the sustainability of healthcare systems and the implications, Expert Review of Pharmacoeconomics & Outcome Research, Vol. 21, No. 4, pp. 527 - 540, Mar, 2021

• The Current Situation Regarding Long-Acting Insulin Analogues Including Biosimilars Among African, Asian, European, and South American Countries; Findings and Implications for the Future (2021-06)

  B. Godman, M. Haque, T. Leong, E. Allocati, S. Kumar, S. Islam, J. Charan, F. Akter, A. Kurdi, C. Vassalo, M. Abu Bakar, S. Abdur Rahim, N. Sultana, F. Deeba, H. Khan, M. Alam, I. Jahan, Z. Kamal, H. Hasan, M. E-Murshid, S. Nahar, M. Haque, S. Dutta, J. Pallavi Abhayanand, R. Jeet Kaur, G. Rwegerera, R. Nascimento, I. Godoi, M. Irfan, A. Amu, P. Matowa, J. Acolatse, R. Incoom, I. Sefah, J. Acharya, S. Opanga, L. Njeri, D. Kimonge, H. Kwon, S. Bae, K. Khuan, A. Abu Bakar, I. Sani, T. Khan, S. Hussain, Z. Saleem, O. Malande, T. Piloya-Were, R. Gambogi, C. Hernandez Ortiz, L. Alutuli, A. Kalungia, I. Hoxha, V. Marković Peković, Б. Тубић, G. Petrova, K. Tachkov, O. Laius, A. Harsanyi, A. Inotai, A. Jakupi, S. Henkuzens, K. Garuoliene, J. Gulbinovic, M. Wladysiuk, J. Rutkowski, I. Mardare, J. Furst, S. McTaggart, S. MacBride-Stewart, C. Pontes, C. Zara, E. Tagoa, R. Banzi, J. Wale, M. Jakovljevic, The Current Situation Regarding Long-Acting Insulin Analogues Including Biosimilars Among African, Asian, European, and South American Countries; Findings and Implications for the Future, Frontiers in public health, Vol. 9, pp. 1 - 21, Jun, 2021

• Utilisation Trend of Long-Acting Insulin Analogues including Biosimilars across Europe: Findings and Implications (2021-10)

  B. Godman, M. Wladysiuk, S. McTaggart, A. Kurdi, E. Allocati, M. Jakovljevic, F. Kalemeera, I. Hoxha, A. Nachtnebel, R. Sauremann, M. Hinteregger, V. Marković Peković, Б. Тубић, G. Petrova, K. Tachkov, J. Slaby, R. Nejezchlebova, I. Selke Krulichova, O. Laius, G. Selke, I. Langer, A. Harsanyi, A. Inotai, A. Jakupi, S. Henkuzens, K. Garuoliene, J. Gulbinovic, P. Vella Bonanno, J. Rutkowski, S. Ingeberg, O. Melien, I. Mardare, J. Furst, S. McBride-Stewart, C. Holmes, C. Pontes, C. Zara, M. Turu Pedrola, M. Hoffman, V. Kourafalos, A. Pisana, R. Banzi, S. Campbell, B. Wettermark, Utilisation Trend of Long-Acting Insulin Analogues including Biosimilars across Europe: Findings and Implications, BioMed Research International, Vol. 2021, No. Article ID 99961, pp. 1 - 16, Oct, 2021

• Biosimilars are essential for sustainable healthcare systems; however, key challenges remain as seen with long-acting insulin analogues (2022-03)

  B. Godman, B. Tubić, E. Allocati, M. Wladysiuk, S. McTaggart, A. Kurdi, M. Haque, S. McBride-Stewart, F. Kalemeera, A. Massele, I. Hoxha, V. Marković Peković, G. Petrova, K. Tachkov, O. Laius, A. Harsanyi, A. Inotai, A. Jakupi, S. Henkuzens, K. Garuoliene, P. Vella Bonanno, J. Rutkowski, I. Mardare, J. Furst, C. Pontes, C. Zara, M. Turu Pedrola, F. Akter, H. Kwon, A. Martin, R. Banzi, J. Wale, J. Gulbinovic, Biosimilars are essential for sustainable healthcare systems; however, key challenges remain as seen with long-acting insulin analogues, Journal of Applied Pharmaceutical Science, Vol. 12, No. 3, pp. 055 - 072, Mar, 2022